CASTELLI, MATTEO
 Distribuzione geografica
Continente #
EU - Europa 206
NA - Nord America 173
AS - Asia 88
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 470
Nazione #
US - Stati Uniti d'America 173
SE - Svezia 107
IT - Italia 52
CN - Cina 50
SG - Singapore 35
RU - Federazione Russa 23
FI - Finlandia 10
DE - Germania 8
IE - Irlanda 3
IN - India 2
RO - Romania 2
AU - Australia 1
EU - Europa 1
FR - Francia 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 470
Città #
Ashburn 45
Milan 42
Princeton 24
Shanghai 24
Lawrence 23
Singapore 19
Moscow 13
New York 10
Helsinki 9
Los Angeles 5
Guangzhou 4
Bologna 3
Dallas 3
Dublin 3
Frankfurt Am Main 3
Xi'an 3
Ancona 2
Beijing 2
Boardman 2
Como 2
Jiaxing 2
Kassel 2
Pune 2
Bloemfontein 1
Borås 1
Changzhi 1
Espoo 1
Hefei 1
Lansing 1
Melbourne 1
Riverside 1
Rockville 1
Rome 1
Santa Clara 1
Seattle 1
Segrate 1
Shijiazhuang 1
Taipei 1
Totale 262
Nome #
Cell-to-cell spread-blocking activity is extremely limited in the sera of HSV-1 and HSV-2 infected subjects 38
A Biologically-validated HCV E1E2 Heterodimer Structural Model 30
A Human Stem Cell-Derived Neurosensory–Epithelial Circuitry on a Chip to Model Herpes Simplex Virus Reactivation 26
Broadly neutralizing anti-influenza human monoclonal antibodies and their possible role in predictive medicine 25
Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro 25
Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis. 24
Detection of low-level HCV variants in DAA treated patients: comparison amongst three different NGS data analysis protocols 23
Nanopore ReCappable sequencing maps SARS-CoV-2 5' capping sites and provides new insights into the structure of sgRNAs 22
Viral Respiratory Pathogens and Lung Injury 21
Interferon-β 1a inhibits SARS-CoV-2 in vitro when administered after virus infection 20
Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein 20
Neutralization Interfering Antibodies: a "Novel" Mechanism of Humoral Immune Mutiny and Viral Evasion? 19
IN VIVO PROTECTION CONFERRED BY HUMAN MONOCLONAL ANTIBODY DIRECTED AGAINST HSV-1 AND 2 19
Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies 19
Influenza B-cells protective epitope characterization: a passkey for the rational design of new broad-range anti-influenza vaccines 18
Characterization of a lineage c.36 sars-cov-2 isolate with reduced susceptibility to neutralization circulating in lombardy, italy 17
Characterization of epitopes recognized by monoclonal antibodies: experimental approaches supported by freely accessible bioinformatic tools 16
HCV E2 core structures and mAbs: something is still missing 16
Destructive extraction of phospholipids from Escherichia coli membranes by graphene nanosheets 16
Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity 16
Peptide-based vaccinology: experimental and computational approaches to target hypervariable viruses through the fine characterization of protective epitopes recognized by monoclonal antibodies and the identification of T-cell-activating peptides. 15
Synergy evaluation of anti-Herpes Simplex Virus type 1 and 2 compounds acting on different steps of virus life cycle 15
Role and potential therapeutic use of antibodies against herpetic infections 15
Unveiling the role of PUS7-mediated pseudouridylation in host protein interactions specific for the SARS-CoV-2 RNA genome 13
Salts drive controllable multilayered upright assembly of amyloid-like peptides at mica/water interface 13
Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens 12
Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening 10
null 1
Totale 524
Categoria #
all - tutte 7.008
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.008


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202 0 0 0 0 0 0 1 0 0 0 0 1
2020/20219 2 0 0 1 0 0 1 0 0 5 0 0
2021/202230 2 1 7 4 0 0 0 2 2 3 3 6
2022/2023186 57 45 25 1 1 27 10 11 7 0 2 0
2023/2024161 0 9 26 30 14 33 4 20 4 9 1 11
2024/202599 45 11 6 19 18 0 0 0 0 0 0 0
Totale 524